

Viral Therapeutics Incorporated

[View the current Viral Therapeutics Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10845-Viral+Therapeutics+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/10845-Viral+Therapeutics+Incorporated.html>)

Contact Details:

95 Brown Road

Ithaca

NY

14850

United States of America

Tel: 607 266 0860

Fax: 607 257 6356

Email:

Recent Publications by Viral Therapeutics Incorporated:



- [Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization.](#)
Alphavirus-derived vectors are being developed for vaccine, gene therapy... 10th May, 2008
Department of Viral Therapeutics and Department of Immunobiology, Chiron- IDrugs. 1998
Oct;1(6):678-85.
- [Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.](#)
We assessed the activities of 24 different antiviral compounds against... 31st July, 2003
Department of Viral Therapeutics, Virology Division, U.S. Army Medical- Antiviral Res. 2003
Jan;57(1-2):13-23.
- [3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice.](#)
3-deazaneplanocin A, an analog of adenosine, is a potent inhibitor of... 14th February, 2003
Virology Division, Department of Viral Therapeutics, United States Army- Antiviral Res. 2002
Jul;55(1):151-9.
- [Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.](#)
Ebola Zaire virus causes lethal hemorrhagic fever in humans, for which... 1st August, 2000
Department of Viral Therapeutics, United States Army Medical Research- Antiviral Res. 2000
Feb;45(2):135-47.

Press Releases on Viral Therapeutics Incorporated:

Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference	24th November, 2009	Cell Therapeutics, Inc.	SEATTLE, Nov. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 21st Annual Piper Jaffray Health Care Conference. The conference will be
NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington	24th November, 2009	National Viral Hepatitis Roundtable	WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti
Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference	23rd November, 2009	Accuray Incorporated	SUNNYVALE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options	23rd November, 2009	National Comprehensive Cancer Network	Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy
Reportlinker Adds Hand Sanitizers - US Market Trends	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Hand Sanitizers - US Market Trends http://www.reportlinker.com/p0164260

BioNews Results for Viral Therapeutics Incorporated



- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Genetic Engineering News: Nov 15 2009 6:06PM Matching: viral therapeutics
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
Therapeutics Daily: Nov 12 2009 1:30PM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
KOTA Territory News: Nov 12 2009 11:33AM Matching: viral therapeutics
- [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)

- KSLA: Nov 12 2009 6:04AM Matching: viral therapeutics*
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Reuters: Nov 12 2009 10:17PM Matching: viral therapeutics
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Yahoo! Canada: Nov 12 2009 10:16PM Matching: viral therapeutics
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:13PM Matching: viral therapeutics
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:11PM Matching: viral therapeutics
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data](#)
Market Wire via MSN Money: Nov 12 2009 9:46PM Matching: viral therapeutics
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Stockwatch: Nov 12 2009 9:42PM Matching: viral therapeutics
 - [Viron To Present Data From Phase II Trial At American Heart Association Conference](#)
Medical News Today: Nov 12 2009 6:30PM Matching: viral therapeutics
 - [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
CNW Telbec: Nov 11 2009 7:32PM Matching: viral therapeutics
 - [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
Pharma Live: Nov 11 2009 8:04PM Matching: viral therapeutics
 - [Viron to Present Data from Phase II Trial at American Heart Association Conference](#)
Individual.com: Nov 11 2009 7:57PM Matching: viral therapeutics

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

